Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

3.52
0.0000
Post-market: 3.520.00000.00%17:50 EDT
Volume:2.39M
Turnover:8.43M
Market Cap:424.50M
PE:-6.64
High:3.61
Open:3.50
Low:3.40
Close:3.52
52wk High:4.89
52wk Low:1.05
Shares:120.60M
Float Shares:116.53M
Volume Ratio:1.06
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5300
EPS(LYR):-0.5300
ROE:-50.20%
ROA:-24.32%
PB:4.12
PE(LYR):-6.64

Loading ...

Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%

Reuters
·
Mar 27

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GlobeNewswire
·
Mar 27

Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting

Reuters
·
Mar 20

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 19

Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis

Reuters
·
Mar 18

Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Mar 18

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

GlobeNewswire
·
Mar 18

Aclaris Therapeutics Raises $20 Million in Equity Financing

TIPRANKS
·
Mar 12

Aclaris Therapeutics sells 5.7 million shares for USD 20 million

Reuters
·
Mar 12

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

GlobeNewswire
·
Mar 03

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 27

Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Feb 26

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

TIPRANKS
·
Feb 26

Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate

Benzinga
·
Feb 26

Aclaris Q4 loss narrows, but misses analysts' expectations

Reuters
·
Feb 26

BRIEF-Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million

Reuters
·
Feb 26

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Feb 26

BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052

Reuters
·
Feb 24

Aclaris Initiates Phase 1b Asthma Trial of Bispecific Antibody ATI-052

Reuters
·
Feb 24

Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Patients With Asthma With Its Novel Bispecific Anti-Tslp/Il-4RΑ Antibody ATI-052

THOMSON REUTERS
·
Feb 24